This approval
extends through Wave 3 of PATH. A full revision is necessary for
the data collection for Wave 4 or yet to be defined sub-studies.
Before submitting the information collection request for Wave 4 to
OMB, NIDA/FDA should report to OMB regarding: a) the response rates
associated with the full baseline wave, including screening,
interview completion, and bio-specimen response; b) Wave 3
retention, recruitment rates for the “age in to adult” and “age in
of shadow” subsamples; c) the results of nonresponse analysis and
statistical approach for addressing non-response, as well as
implications for the study going forward; and d) the statistical
approach to be applied to the bio-specimen data to address
potential non-response bias from lower consent and cooperation
rates with this aspect of the study. Per prior terms of clearance,
NIDA and FDA will create a public use dataset from each wave’s
data, making it available to the public on-line within 18 months of
completion of each wave. Data underlying government-funded
scientific publications will be made available to the public,
consistent with NIH guidelines for implementing OSTP’s Public
Access to the Results of Federally Funded Research. This study is
not specifically designed to provide nationally representative
estimates of prevalence. As such, FDA and NIDA will always present
such cross-sectional prevalence estimates in conjunction with
estimates from HHS’ signature nationally representative studies
such as CPS-TUPS, NHIS, NATS, and NSDUH.
Inventory as of this Action
Requested
Previously Approved
08/31/2018
36 Months From Approved
09/30/2016
192,858
0
192,858
54,434
0
59,023
0
0
0
This is a revision request (OMB
0925-0664, expires 9/30/2016) for the Population Assessment of
Tobacco and Health (PATH) Study to conduct the third wave of data
collection. The PATH Study is a national longitudinal cohort study
of tobacco use behavior and health among the U.S. household
population of adults age 18 and older and youth ages 12 to 17. The
Study conducts annual interviews and collects biospecimens from
adults to assess within-person changes and between-person
differences in tobacco-product use behaviors and related health
conditions over time. Its longitudinal, population-based data will
help to enhance the evidence base that informs the Food and Drug
Administration's regulatory actions under the Family Smoking
Prevention and Control Act to protect the Nation's public health
and reduce its burden of tobacco-related morbidity and
mortality.
US Code:
42
USC 285o Name of Law: Public Health Service Act
This is a revision request (OMB
0925-0664, expires 9/30/2016) for the Population Assessment of
Tobacco and Health (PATH) Study to conduct the third wave of data
collection. There is a reduction of 4,589 estimated burden hours
between Wave 2 (59,023) and Wave 3 (54,434). Factors accounting for
this reduction include the following: (1) an 86 percent response
rate for interviews with continuing adults, (2) an 87 percent
response rate for interviews with aged-up adults, (3) a 91 percent
response rate for interviews with continuing youth, and (4) an 89
percent response rate for interviews with aged-up youth.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.